All In Biotech

Drug Trial Radar · NCT00002514

Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission

Phase III Randomized Trial of Autologous and Allogeneic Stem Cell Transplantation Versus Intensive Conventional Chemotherapy in Acute Lymphoblastic Leukemia in First Remission

Last checked: Nov 19, 2026Latest source record: Jun 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,929 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,929

Actual

Start

May 7, 1993

Primary completion

Dec 2006

Sponsor

Lead sponsor
Eastern Cooperative Oncology GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI); Medical Research Council
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 15 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.

Conditions

  • Leukemia

Interventions

  • sargramostimBiological

  • asparaginaseDrug

  • cyclophosphamideDrug

  • cytarabineDrug

  • daunorubicin hydrochlorideDrug

  • dexamethasoneDrug

  • etoposideDrug

  • imatinib mesylateDrug

  • leucovorin calciumDrug

  • mercaptopurineDrug

  • methotrexateDrug

  • prednisoneDrug

  • thioguanineDrug

  • vincristine sulfateDrug

  • allogeneic bone marrow transplantationProcedure

  • autologous bone marrow transplantationProcedure

  • peripheral blood stem cell transplantationProcedure

  • radiation therapyRadiation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: All patients were followed for 2 years

Locations

94 sites in 1 country. Site status is shown where the registry gives one.

  • Aurora Presbyterian Hospital

    Aurora, Colorado

  • Boulder Community Hospital

    Boulder, Colorado

  • Penrose Cancer Center at Penrose Hospital

    Colorado Springs, Colorado

  • Porter Adventist Hospital

    Denver, Colorado

  • Presbyterian - St. Luke's Medical Center

    Denver, Colorado

  • St. Joseph Hospital

    Denver, Colorado

  • Rose Medical Center

    Denver, Colorado

  • CCOP - Colorado Cancer Research Program

    Denver, Colorado

  • Swedish Medical Center

    Englewood, Colorado

  • St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center

    Grand Junction, Colorado

  • Sky Ridge Medical Center

    Lone Tree, Colorado

  • Hope Cancer Care Center at Longmont United Hospital

    Longmont, Colorado

  • St. Mary - Corwin Regional Medical Center

    Pueblo, Colorado

  • North Suburban Medical Center

    Thornton, Colorado

  • Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center

    Farmington, Connecticut

  • George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus

    New Britain, Connecticut

  • Rush-Copley Cancer Care Center

    Aurora, Illinois

  • Evanston Northwestern Healthcare - Evanston Hospital

    Evanston, Illinois

  • Hinsdale Hematology Oncology Associates

    Hinsdale, Illinois

  • Joliet Oncology-Hematology Associates, Limited - West

    Joliet, Illinois

  • Carle Cancer Center at Carle Foundation Hospital

    Urbana, Illinois

  • CCOP - Carle Cancer Center

    Urbana, Illinois

  • Methodist Cancer Center at Methodist Hospital

    Indianapolis, Indiana

  • Saint Anthony Memorial Health Centers

    Michigan City, Indiana

  • Cedar Rapids Oncology Associates

    Cedar Rapids, Iowa

  • Siouxland Hematology-Oncology Associates, LLP

    Sioux City, Iowa

  • Mercy Medical Center - Sioux City

    Sioux City, Iowa

  • St. Luke's Regional Medical Center

    Sioux City, Iowa

  • Tufts-NEMC Cancer Center

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Baystate Regional Cancer Program at D'Amour Center for Cancer Care

    Springfield, Massachusetts

  • Saint Joseph Mercy Cancer Center

    Ann Arbor, Michigan

  • CCOP - Michigan Cancer Research Consortium

    Ann Arbor, Michigan

  • Oakwood Cancer Center at Oakwood Hospital and Medical Center

    Dearborn, Michigan

  • Genesys Hurley Cancer Institute

    Flint, Michigan

  • Hurley Medical Center

    Flint, Michigan

  • Van Elslander Cancer Center at St. John Hospital and Medical Center

    Grosse Pointe Woods, Michigan

  • Foote Hospital

    Jackson, Michigan

  • Borgess Medical Center

    Kalamazoo, Michigan

  • West Michigan Cancer Center

    Kalamazoo, Michigan

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.